公开(公告)号：WO2013063114A8

公开(公告)日：2014-03-20

申请号：PCT/US2012061690

申请日：2012-10-24

Applicant: ABBVIE INC ,  HSIEH CHUNG-MING ,  BENATUIL LORENZO ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN ,  PEREZ JENNIFER ,  ZHONG SUJU ,  GOODREAU CARRIE ,  CLABBERS ANCA

Inventor： HSIEH CHUNG-MING ,  BENATUIL LORENZO ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN ,  PEREZ JENNIFER ,  ZHONG SUJU ,  GOODREAU CARRIE ,  CLABBERS ANCA

IPC: C07K16/24 ,  C07K16/46

CPC classification number: C07K16/241 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6847 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863

Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-a), e.g., human TNF-a, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了与肿瘤坏死因子-α（TNF-α）结合的分离的结合蛋白，例如其抗体结合部分，例如人TNF-α，以及相关的基于抗体的组合物和分子。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。

公开(公告)号：WO2013063095A1

公开(公告)日：2013-05-02

申请号：PCT/US2012/061666

申请日：2012-10-24

Applicant: ABBVIE INC. ,  HSIEH, Chung-Ming ,  IVANOV, Alexander ,  WAEGELL, Wendy

Inventor： HSIEH, Chung-Ming ,  IVANOV, Alexander ,  WAEGELL, Wendy

IPC: C07K16/22 ,  C07K16/24 ,  A61K39/395 ,  A61P19/02 ,  A61P1/00

CPC classification number: C07K16/468 ,  A61K31/353 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/519 ,  A61K31/56 ,  A61K38/13 ,  A61K38/1793 ,  A61K38/18 ,  A61K38/1808 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/191 ,  A61K38/2026 ,  A61K38/2066 ,  A61K38/2073 ,  A61K38/217 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.

Abstract translation: 与用于治疗，预防和诊断硬化性相关疾病和用于检测细胞，组织，样品和组合物中的硬化蛋白或硬化蛋白和TNF的组合物和方法一起描述了结合硬化蛋白或硬化蛋白和TNF的蛋白质。

公开(公告)号：WO2012024187A1

公开(公告)日：2012-02-23

申请号：PCT/US2011/047622

申请日：2011-08-12

Applicant: ABBOTT LABORATORIES ,  ABBOTT GMBH & CO. KG ,  BARGHORN, Stefan ,  HILLEN, Heinz ,  STRIEBINGER, Andreas ,  GIAISI, Simone ,  EBERT, Ulrich ,  HSIEH, Chung-Ming

Inventor： BARGHORN, Stefan ,  HILLEN, Heinz ,  STRIEBINGER, Andreas ,  GIAISI, Simone ,  EBERT, Ulrich ,  HSIEH, Chung-Ming

IPC: C07K16/18 ,  A61P25/28

CPC classification number: C07K7/06 ,  A61K39/3955 ,  C07K16/18 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/41

Abstract: The present invention relates to amyloid-beta (Αβ) binding proteins. Antibodies of the inven- tion have high affinity to Αβ(20-42) globulomer or any Αβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Abstract translation: 本发明涉及淀粉样蛋白-β（ββ）结合蛋白。 本发明的抗体对αβ（20-42）球聚体或包含球聚体表位的任何β形式具有高亲和力。 还提供了制备方法和使用本发明抗体的方法。

公开(公告)号：WO2011025964A2

公开(公告)日：2011-03-03

申请号：PCT/US2010/047006

申请日：2010-08-27

Applicant: ABBOTT LABORATORIES ,  BENATUIL, Lorenzo ,  BOGHAERT, Erwin, R. ,  GU, Jijie ,  HARRIS, Maria ,  HICKSON, Jonathan, A. ,  HSIEH, Chung-Ming ,  KUTSKOVA, Yuliya ,  LI, Yingchun ,  LIU, Zhihong ,  MORGAN-LAPPE, Susan

Inventor： BENATUIL, Lorenzo ,  BOGHAERT, Erwin, R. ,  GU, Jijie ,  HARRIS, Maria ,  HICKSON, Jonathan, A. ,  HSIEH, Chung-Ming ,  KUTSKOVA, Yuliya ,  LI, Yingchun ,  LIU, Zhihong ,  MORGAN-LAPPE, Susan

IPC: C07K16/28

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR移植抗体，人抗体和其DLL4结合片段，以高亲和力结合DLL4的蛋白，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，尤其用于治疗或预防肿瘤血管生成和/或其他血管生成依赖性疾病，例如眼新血管形成或以异常DLL4表达或活性为特征的血管生成非依赖性疾病，如自身免疫 包括多发性硬化症的疾病。

公开(公告)号：WO2010006059A8

公开(公告)日：2010-09-02

申请号：PCT/US2009049953

申请日：2009-07-08

Applicant: ABBOTT LAB ,  GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

Inventor： GU JIJIE ,  HUTCHINS CHARLES W ,  ZHU RONG-RONG ,  SHEN JIANWEI ,  HARRIS MARIA C ,  BELANGER EILEEN ,  MURTAZA ANWAR ,  TARCSA EDIT ,  STINE WILLIAM B ,  HSIEH CHUNG-MING

IPC: A61K39/395

CPC classification number: C07K16/18 ,  A61K31/405 ,  A61K31/573 ,  A61K39/39533 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Abstract translation: 本发明包括前列腺素E2（PGE2）结合蛋白。 本发明涉及野生型，嵌合，CDR移植和人源化的抗体。 优选的抗体对前列腺素E2具有高亲和力并且在体外和体内中和前列腺素E2的活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗原结合部分可用于检测前列腺素E2和用于抑制前列腺素E2活性，例如，在患有前列腺素E2活性是有害的病症的人类受试者中。

公开(公告)号：WO2008082651A3

公开(公告)日：2008-07-10

申请号：PCT/US2007/026482

申请日：2007-12-28

Applicant: ABBOTT LABORATORIES ,  HSIEH, Chung-ming ,  MCRAE, Bradford, L. ,  KUTSKOVA, Yuliya ,  MEMMOTT, John, E. ,  ROGUSKA, Michael ,  TOMLINSON, Ian ,  TUNA, Mihriban ,  GRANT, Steven ,  ENEVER, Carrie

Inventor： HSIEH, Chung-ming ,  MCRAE, Bradford, L. ,  KUTSKOVA, Yuliya ,  MEMMOTT, John, E. ,  ROGUSKA, Michael ,  TOMLINSON, Ian ,  TUNA, Mihriban ,  GRANT, Steven ,  ENEVER, Carrie

IPC: A61K39/00

Abstract: The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-l α and human IL-I β. The dual specific antibodies of the invention also neutralize both human IL-I α and human IC-I β. The invention also provides domain antibodies (dAbs) specific for human IL-l α and human IL-l β.

公开(公告)号：WO2021262791A1

公开(公告)日：2021-12-30

申请号：PCT/US2021/038591

申请日：2021-06-23

Applicant: MERCK SHARP & DOHME CORP. ,  BAKER, Jeanne, E. ,  PARMENTIER BATTEUR, Sophie ,  CHEN, Ming-Tang ,  CHENG, Alan, C. ,  HSIEH, Chung-Ming ,  MIECZKOWSKI, Carl ,  SUON, Sokreine

Inventor： BAKER, Jeanne, E. ,  PARMENTIER BATTEUR, Sophie ,  CHEN, Ming-Tang ,  CHENG, Alan, C. ,  HSIEH, Chung-Ming ,  MIECZKOWSKI, Carl ,  SUON, Sokreine

IPC: A61K39/395 ,  C07K16/18 ,  A61P25/28 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

公开(公告)号：WO2012088094A3

公开(公告)日：2012-10-04

申请号：PCT/US2011066126

申请日：2011-12-20

Applicant: ABBOTT LAB ,  HSIEH CHUNG-MING

Inventor： HSIEH CHUNG-MING

IPC: A61K47/48 ,  C07K16/24

CPC classification number: A61K51/1021 ,  C07K16/245 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention describes IL-1a binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1a. Binding proteins of the invention have high affinity for IL-1a and neutralize IL-1a activity. A binding protein of the invention can be a full-length antibody or an IL-1a -binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1a binding proteins of the invention are useful for detecting IL-1a and for inhibiting IL-1a activity, including in a human subject suffering from a disease or disorder in which IL-1a activity is detrimental.

Abstract translation: 本发明描述了IL-1a结合蛋白，包括结合IL-1a的嵌合，CDR移植和人源化抗体。 本发明的结合蛋白对IL-1a具有高亲和力并中和IL-1a活性。 本发明的结合蛋白可以是全长抗体或其IL-1a结合部分。 还描述了制备方法和使用本发明的结合蛋白的方法。 本发明的IL-1a结合蛋白可用于检测IL-1a和抑制IL-1a活性，包括在患有IL-1a活性有害的疾病或病症的人类受试者中。

公开(公告)号：WO2012088094A2

公开(公告)日：2012-06-28

申请号：PCT/US2011/066126

申请日：2011-12-20

Applicant: ABBOTT LABORATORIES ,  HSIEH, Chung-ming

Inventor： HSIEH, Chung-ming

IPC: A61K39/00

CPC classification number: A61K51/1021 ,  C07K16/245 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention describes IL-1α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1α. Binding proteins of the invention have high affinity for IL-1α and neutralize IL-1α activity. A binding protein of the invention can be a full-length antibody or an IL-1α -binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1α binding proteins of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, including in a human subject suffering from a disease or disorder in which IL-1α activity is detrimental.

Abstract translation: 本发明描述了IL-1α结合蛋白，包括结合IL-1α的嵌合，CDR移植和人源化抗体。 本发明的结合蛋白对IL-1α具有高亲和力并中和IL-1α活性。 本发明的结合蛋白可以是全长抗体或其IL-1α结合部分。 还描述了制备方法和使用本发明的结合蛋白的方法。 本发明的IL-1α结合蛋白可用于检测IL-1α并抑制IL-1α活性，包括患有IL-1α活性有害的疾病或病症的人类受试者。

公开(公告)号：WO2011143562A3

公开(公告)日：2012-03-01

申请号：PCT/US2011036444

申请日：2011-05-13

Applicant: ABBOTT LAB ,  WU CHENGBIN ,  AMBROSI DOMINIC J ,  HSIEH CHUNG-MING ,  GHAYUR TARIQ

Inventor： WU CHENGBIN ,  AMBROSI DOMINIC J ,  HSIEH CHUNG-MING ,  GHAYUR TARIQ

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C12P21/08

CPC classification number: C07K16/245 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/007 ,  A61K9/0085 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6879 ,  C07K14/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869 ,  G01N2333/545 ,  G01N2800/00

Abstract: Proteins that bind IL-1a and IL-1ß are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1 -related disorders and for detecting IL-1a and IL-1ß in cells, tissues, samples, and compositions.

Abstract translation: 描述了结合IL-1α和IL-1β的蛋白质及其在用于治疗，预防和诊断IL-1相关疾病的组合物和方法中的用途，并用于检测细胞，组织，样品中的IL-1α和IL-1β， 和组合物。